Herpes zoster vaccine (GSK 1437173A)

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Herpes ZosterHerpes Zoster Vaccine

Phase 3

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

CompletedNCT01767467

GlaxoSmithKlineHerpes Zoster

Start: 2013-03-01End: 2017-01-06Updated: 2018-06-06

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

CompletedNCT02075515

GlaxoSmithKlineHerpes Zoster, Herpes Zoster Vaccine

Start: 2014-08-13End: 2016-04-25Updated: 2021-05-14

Related Papers

Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance.

2021-11-3010 citations

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.

2019-08-06168 citations

149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial

Open Forum Infectious Diseases2018-11-019 citations

A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su

Vaccine2017-10-2411 citations

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial

Open Forum Infectious Diseases2017-01-0113 citations